This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection .

Oral presentation

O124 Efavirenz and rifampicin in the South African context: is there a need to dose increase efavirenz with concurrent rifampicin therapy?

C Orrell¹, K Cohen², P Ive³, I Sanne³ and R Wood¹

¹  Desmond Tutu HIV Centre, UCT, Cape Town, South Africa

²  Division of Clinical Pharmacology, UCT, Cape Town, South Africa

³  Wits Health Consortium, Johannesburg, South Africa

corresponding author email

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Journal of the International AIDS Society 2008, 11(Suppl 1):O9doi:10.1186/1758-2652-11-S1-O9

Published:	10 November 2008

First paragraph (this article has no abstract)

In the developing world many people are co-infected with HIV and tuberculosis (TB). Recommended first-line antiretroviral therapy (ART) commonly includes efavirenz (EFV). Anti-tuberculous therapy includes rifampicin (RFN). There remains debate about whether a dose increase of EFV from the standard dose of 600 mg to an increased dose of 800 mg daily is required with concomitant RFN, which induces cytochrome p450 isoenzymes that may reduce levels of EFV.